Once overlooked as the merely the human body’s plumbing, the lymphatic system is emerging as a new therapeutic frontier, ...

On this weeks episode of the Business of Biotech, Bret Bostwick, M.D., Venture Partner at Breyer Capital, a family office, talks about his path from medical geneticist to CNS drug development and ...

Life sciences distribution is shifting toward AI-powered, resilient networks that improve speed, efficiency, compliance, and ...

On this weeks episode of the Business of Biotech, Simeon George, M.D., Cofounder and CEO at SR One Capital Management, returns to the show to talk about how SR One evaluates biotech investment targets ...

Autologous CAR-T therapy has transformed cancer treatment, validating the idea that engineered immune cells can produce durable therapeutic responses in patients with otherwise limited options. Yet as ...

On this week's episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to ...

A publicly traded life sciences company considering a new director knows how to investigate. It will examine the candidate’s career, reputation, relationships, conflicts, financial interests, and ...

Managing clinical trial disclosure can be challenging with the ever-evolving regulatory landscape, and varying requirements across different jurisdictions and regulatory bodies. New and updated ...

On this week's episode of the Business of Biotech, Philina Lee, Ph.D., CEO at AdvanCell, explains how lead-based targeted alpha therapies can unlock deeper, more durable cancer responses, and why ...

My father was a lawyer in New York City. He built his own practice from nothing, the way immigrants do. Through discipline, reputation, a little grit, and an almost stubborn insistence on doing right ...